It also helps reduce weight in some people
The Semaglutide cohort compared to the non-GLP-1RA anti-diabetes medications cohort included more women, had a higher prevalence of problems with lifestyle, obesity, obesity-associated comorbidities, mental disorders, and substance use disorders
Its a dual-agonist meaning it targets both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously
However, they are both suitable options for those struggling to lose weight, and they both affect specific areas of the body to curb your appetite
Book a free online consultation with one of our weight loss experts by using the button below and see if GLP-1 Shots is right for you
Dual agonist survodutide for obesity: a dosefinding Phase 2 trial